Synopsis: Ind-Swift Labs shares rose 4%, driven by a sharp profit turnaround. Q3FY26 net profit jumped 19% QoQ to Rs. 9.54 Cr, while YoY sales grew 17% to Rs. 151 Cr and EPS hit Rs. 1.17.
This company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor is now in focus after reporting its Q3 results with a turnaround in net profit
With a market capitalisation of Rs. 912 cr, the shares of Ind-Swift Laboratories Ltd are currently trading at Rs. 112 per share, increasing 4% in today’s market session, making a high of Rs. 118.05, up from its previous close of Rs. 113.34 per share. The stock has gained 8% over the past year, is up 23% year-to-date, and has increased 4% in the last six months.
Q3 Results
Quarter-on-Quarter (QoQ) performance
Ind-Swift Labs showed mixed trends on a QoQ basis. Sales slightly declined from Rs. 153 Cr in Q2FY26 to Rs. 151 Cr in Q3FY26, reflecting a 1% decrease. However, profitability improved sharply. EBITDA rose from Rs. 1.47 Cr to Rs. 4.17 Cr, an impressive 183% increase.
Net Profit increased from Rs. 7.99 Cr to Rs. 9.54 Cr, a 19% rise. Consequently, EPS also increased from Rs. 0.98 to Rs. 1.17, representing a 19% growth QoQ. This indicates that while revenue remained almost flat, operational efficiency and cost management significantly boosted profitability in the quarter.
Year-on-Year (YoY) performance
On a YoY basis, Ind-Swift Labs demonstrated strong growth. Sales rose from Rs. 129 Cr in Q3FY26 to Rs. 151 Cr in Q3FY26, marking a 17% increase. Profitability turnaround was remarkable. EBITDA moved from a negative Rs. 6.65 Cr to Rs. 4.17 Cr, a massive improvement.
Net Profit jumped from a loss of Rs. 5.49 Cr to a gain of Rs. 9.54 Cr. EPS similarly recovered from a negative Rs. 0.93 to Rs. 1.17, a 225.8% increase, highlighting a strong recovery in earnings.
Ind-Swift Laboratories Limited has informed that there has been no deviation or variation in the utilisation of funds raised through its preferential issue of convertible warrants. For the quarter ended 31 December 2025, the company utilised Rs. 208.95 crore out of Rs. 209.41 crore raised (from a total issue size of Rs. 314.60 crore) strictly for the stated objects, including business expansion, investment in subsidiaries, working capital, and general corporate purposes.
About the company
Ind-Swift Group is a globally trusted pharmaceutical company known for innovation, quality, and ethical practices. In India, its Ethical and Generic Healthcare Divisions deliver high-quality, affordable medicines across multiple therapeutic areas, ensuring access from urban centres to rural communities. The company delivers high-quality, affordable medicines across diverse therapeutic areas, including anti-infectives, cardiology, gastroenterology, neurology, and gynaecology.
The company is almost debt-free, with a debt-to-equity ratio of 0.02. While the industry P/E stands at 29.4, the stock trades at a P/E of 19.2. It has delivered a compounded profit growth of 16% over the past 5 years, and the stock price has grown at a CAGR of 20% over the last 3 years.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
